Micafungin Mylan

Micafungin, the active ingredient in Micafungin Mylan, is a echinocandin antifungal presented as an injection for intravenous use. It treats invasive candidiasis, candidemia, esophageal candidiasis and febrile neutropenia with suspected fungal infection in appropriate patients.

GNH USA supplies Micafungin Mylan as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

Micafungin is used to treat fungal infections within the Candida disease spectrum.

- Invasive candidiasis: effective treatment to eradicate systemic Candida infection. - Candidemia: clears bloodstream Candida organisms and reduces mortality. - Esophageal candidiasis: resolves mucosal lesions and alleviates dysphagia. - Febrile neutropenia with suspected fungal infection: provides empirical antifungal coverage to improve outcomes.

Micafungin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fever: transient elevation of body temperature. - Nausea: mild gastrointestinal upset. - Headache: occasional mild headache. - Elevated liver enzymes: mild increase in ALT/AST.

Serious or Rare Side Effects: - Hepatotoxicity: significant liver injury requiring monitoring. - Severe hypersensitivity: rash, angioedema, or anaphylaxis. - Infusion-related reactions: hypotension, dyspnea, or chest discomfort.

Before initiating therapy, clinicians should evaluate patient-specific factors and monitor for potential complications. - Renal impairment: monitor kidney function during therapy. - Hepatic dysfunction: assess liver enzymes before and during treatment. - Concomitant azoles: avoid coadministration due to potential antagonism. - Pregnancy: use only if benefit outweighs risk; data limited. - Pediatric use: safety not established; use under specialist guidance. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin may interact with several concomitant medications, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Rifampin: strong enzyme inducer that markedly lowers micafungin exposure. - Azole antifungals (e.g., fluconazole, voriconazole): may antagonize efficacy. - Carbamazepine: reduces micafungin plasma concentrations.

Moderate Interactions (Monitor Closely): - Cyclosporine: may increase cyclosporine levels; monitor concentrations. - Tacrolimus: potential increase in tacrolimus exposure; adjust dose as needed. - Warfarin: possible alteration of INR; monitor coagulation parameters.